Saletu B, Grünberger J, Cepko H
Psychiatric University Clinic of Vienna, Section of Pharmapsychiatry, Austria.
Int J Clin Pharmacol Ther Toxicol. 1987 Aug;25(8):421-37.
In a double-blind, placebo-controlled study, the encephalotropic and psychotropic properties of Ro 23-0364, a novel imidazobenzodiazepine with mixed benzodiazepine agonist/antagonist properties, were investigated as compared with the pure agonist diazepam utilizing quantitative EEG and psychometric analyses as well as clinical observations. Ten normal volunteers received randomized (latin square) and at weekly intervals single oral doses of placebo, 0.25 mg, 0.5 mg and 1.0 mg Ro 23-0364 and 10 mg diazepam as reference drug. EEG-recordings and evaluation of pulse, blood pressure and side effects were carried out at the hours 0, 1, 2, 4, 6, and 8; psychometric tests at the same times except the first hour. Computer-assisted spectral analyses of the EEG demonstrated after 10 mg diazepam a typical "anxiolytic" pharmaco-EEG profile characterized by an increase of beta-activity, decrease of alpha-activity and absolute and relative power of the dominant frequency, furthered by an acceleration of the centroid of the total activity and a slowing of the centroid of the combined delta/theta-activity. In addition, there was an increase of delta-activity specifically in the resting recording condition suggesting also sedative properties of the reference compound. Ro 23-0364 induced in the vigilance-controlled recordings a similar profile as diazepam-although less pronounced-thereby exhibiting tranquilizing qualities. However, in the resting condition the most consistent change was an augmentation of delta/theta-activity along with an attenuation of alpha-activity, which was evident already in the lower dosage range and is reminiscent also of changes seen after sedative neuroleptic drugs (although the centroid slowing was missing). These data indicate a selective sedation of the mixed agonist/antagonist in the resting state. Dose-efficacy calculations based on EEG-changes demonstrated the reference compound, 1.0 and 0.5 mg Ro 23-0364 different from placebo. 10 mg diazepam was by far the most CNS-active compound inducing significantly more changes than the three doses of the mixed agonist/antagonist. Within the latter the two higher doses were superior to 0.25 mg but could not be differentiated from each other. Time-efficacy calculations showed the maximal encephalotropic effect of diazepam within the first two hours while the peak effect of 1.0 mg and 0.5 mg Ro 23-0364 fell into the 6th and 4th hour, respectively. There were no differences between the time periods after 0.25 mg although there was a trend towards high activity in the first two hours followed by a trough in the 4th and 6th hour and thereafter again an increase.(ABSTRACT TRUNCATED AT 400 WORDS)
在一项双盲、安慰剂对照研究中,与纯激动剂地西泮相比,利用定量脑电图和心理测量分析以及临床观察,对具有混合苯二氮䓬激动剂/拮抗剂特性的新型咪唑并苯二氮䓬Ro 23-0364的亲脑性和精神otropic特性进行了研究。10名正常志愿者接受随机(拉丁方)分组,每周一次单剂量口服安慰剂、0.25毫克、0.5毫克和1.0毫克Ro 23-0364以及作为参比药物的10毫克地西泮。在0、1、2、4、6和8小时进行脑电图记录以及脉搏、血压和副作用评估;除第一小时外,在相同时间进行心理测量测试。脑电图的计算机辅助频谱分析显示,10毫克地西泮后呈现典型的“抗焦虑”药物脑电图特征,表现为β活性增加、α活性降低以及主导频率的绝对和相对功率降低,同时总活动质心加速和δ/θ组合活动质心减慢。此外,在静息记录条件下,δ活性增加,这也表明参比化合物具有镇静特性。Ro 23-0364在警觉控制记录中诱导出与地西泮相似的特征——尽管不太明显——从而表现出镇静作用。然而,在静息状态下,最一致的变化是δ/θ活性增强以及α活性减弱,这在较低剂量范围内就已明显,也让人联想到镇静性抗精神病药物后的变化(尽管质心减慢不存在)。这些数据表明混合激动剂/拮抗剂在静息状态下具有选择性镇静作用。基于脑电图变化的剂量-效应计算表明,参比化合物、1.0毫克和0.5毫克Ro 23-0364与安慰剂不同。10毫克地西泮是迄今为止中枢神经系统活性最强的化合物,诱导的变化明显多于混合激动剂/拮抗剂的三个剂量。在后者中,两个较高剂量优于0.25毫克,但彼此无法区分。时间-效应计算表明,地西泮在前两小时内产生最大的亲脑效应,而1.0毫克和0.5毫克Ro 23-0364的峰值效应分别出现在第6小时和第4小时。0.25毫克后的时间段之间没有差异,尽管有一个趋势,即在最初两小时内活性较高,随后在第4小时和第6小时出现低谷,此后再次增加。(摘要截断于400字)